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Abstract
The rising prevalence of gestational diabetes mellitus (GDM) affects up to 18% of pregnant women with immediate and
long-term metabolic consequences for both mother and infant. Abnormal glucose uptake and lipid oxidation are hallmark
features of GDM prompting us to use an exploratory proteomics approach to investigate the cellular mechanisms
underlying differences in skeletal muscle metabolism between obese pregnant women with GDM (OGDM) and obese
pregnant women with normal glucose tolerance (ONGT). Functional validation was performed in a second cohort of obese
OGDM and ONGT pregnant women. Quantitative proteomic analysis in rectus abdominus skeletal muscle tissue collected at
delivery revealed reduced protein content of mitochondrial complex I (C-I) subunits (NDUFS3, NDUFV2) and altered content
of proteins involved in calcium homeostasis/signaling (calcineurin A, a1-syntrophin, annexin A4) in OGDM (n=6) vs. ONGT
(n=6). Follow-up analyses showed reduced enzymatic activity of mitochondrial complexes C-I, C-III, and C-IV (260–75%) in
the OGDM (n=8) compared with ONGT (n=10) subjects, though no differences were observed for mitochondrial complex
protein content. Upstream regulators of mitochondrial biogenesis and oxidative phosphorylation were not different
between groups. However, AMPK phosphorylation was dramatically reduced by 75% in the OGDM women. These data
suggest that GDM is associated with reduced skeletal muscle oxidative phosphorylation and disordered calcium
homeostasis. These relationships deserve further attention as they may represent novel risk factors for development of GDM
and may have implications on the effectiveness of physical activity interventions on both treatment strategies for GDM and
for prevention of type 2 diabetes postpartum.
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Introduction
Gestational diabetes mellitus (GDM) is a rapidly growing public
health concern. Adoption of new diagnostic criteria recommended
by the American Diabetes Association (ADA) [1,2] estimates a
global prevalence of nearly one in five women (,18%) who are
considered at risk for GDM. Obesity occurs in ,one in three
women of child-bearing age [1,3] and is a driving force
accelerating the prevalence of GDM. GDM not only complicates
pregnancy by increasing risk of pre-eclampsia and cesarean
delivery, but is an independent risk factor for excess fetal growth
and childhood obesity [3–7], and a consequence of even greater
insulin resistance and nutrient availability than associated with
maternal obesity alone [4–8]. In addition, GDM diagnosis
identifies a population of women at markedly increased risk for
future diabetes [8,9], in part due to abnormal skeletal muscle
signaling. Up to fifty percent of women diagnosed with GDM will
go on to develop type 2 diabetes (T2DM) [9–11], and physical
activity and dietary interventions to prevent this progression have
been disappointing due to compliance difficulties [10–13]. Thus,
understanding the pathogenesis of GDM is extremely important
PLOS ONE | www.plosone.org 1 September 2014 | Volume 9 | Issue 9 | e106872from a public health perspective for both maternal and child
health.
Late in gestation, due to the demands of the placental-fetal unit
and rapid depletion of glycogen stores, all women exhibit a shift in
metabolism to increase reliance on lipid for metabolic substrate, a
term called accelerated starvation. This metabolic shift is
accompanied by a large decrease in skeletal muscle insulin
sensitivity (250%), both of which serve to allow for increased
glucose supply to the growing fetus [12–14]. Women with GDM,
however, demonstrate lower rates of whole body lipid oxidation
both during early and late gestation [14,15], with a less robust shift
from glucose to lipid metabolism in late pregnancy compared with
their normal glucose tolerant (NGT) counterparts [15–17].
Skeletal muscle, by virtue of its mass, is the principle site of
glucose and lipid oxidation [3,16–18], and therefore plays an
important role in whether fuels are utilized by maternal tissues or
shunted across the placenta to the developing fetus. The pathways
underlying insulin resistance in GDM are well studied and
multifactorial. However, little is known about the cellular
mechanisms for altered skeletal muscle lipid or glucose metabo-
lism, which is likely to significantly alter nutrient availability, thus
increasing risk for increased fetal fat accretion and an increased
risk of childhood obesity in offspring of women with GDM
[3,18,19].
Therefore, the purpose of this study was to employ a discovery
proteomic approach to identify candidate proteins that may
underlie differences in skeletal muscle metabolism in obese, GDM
pregnant women. The advantage of proteomic analysis, as
opposed to a transcriptomic approach, is that we are able to
measure content of global functional molecules involved in skeletal
muscle metabolism rather than expression of genes that may or
may not be related to protein content. We used an established
quantitative proteomic analysis [19,20] to compare skeletal muscle
of obese pregnant women with GDM (OGDM) with obese
pregnant women with NGT (ONGT). We then carried out a
functional validation in a second, larger cohort of obese pregnant
women with and without GDM. We are the first to demonstrate
that several proteins of the mitochondrial electron transport
system (ETS) are downregulated in the OGDM women, a factor
we corroborated by demonstrating reduced activity of several
enzyme complexes of the ETS in the second cohort of women.
Proteomic analysis also revealed disruptions in calcium signaling/
homeostasis proteins in skeletal muscle of the obese women with
GDM, several of which may be related to cellular and
mitochondrial stress. Along with a marked reduction in phos-
phorylated AMPK in the OGDM women, these results suggest
that reduced capacity for skeletal muscle lipid or glucose oxidation
may play an important role in the pathogenesis of GDM and may
contribute to increased nutrient exposure to the fetus, potentially
resulting in excess infant adiposity and long-term health conse-
quences in the offspring.
Research Design and Methods
Study 1: Proteomic Analysis
Ethics Statement. Approval for this study was obtained from
the East Carolina University Policy and Review Committee on
Human Research and the Colorado Multiple Institutional Review
Board at the University of Colorado Hospital. Written informed
consent was obtained from all participants prior to cesarean
delivery.
Patients and Sample Collection. Pregnant women over 21
years of age were screened for GDM between 24–28 weeks
gestation and were diagnosed according to Carpenter and
Coustan (CC) criteria [20,21] using a 3-hour 100 g oral glucose
tolerance test. Women with polycystic ovarian syndrome, pre-
eclampsia, and macrovascular complications were excluded. All
women with GDM were treated with insulin during the last 10–15
weeks of pregnancy to maintain normoglycemia. Body mass index
(BMI) was calculated based on measurements from patients’ first
antenatal visit (,12 weeks gestation) and, in both groups, only
those with a BMI of .30 kg/m
2 were included. Plasma insulin
and glucose were measured in samples obtained immediately prior
to cesarean delivery.
Between 300–500 mg of rectus abdominus skeletal muscle tissue
were obtained from a total of 12 obese pregnant women
undergoing elective cesarean delivery (term, ,37 weeks gestation;
6 ONGT women, 6 OGDM). Rectus abdominus is of mixed
muscle fiber type [19,21]. Dissections of skeletal muscle were
obtained within 10 min of delivery, dissected free from visible
adipose and connective tissues, and snap frozen in liquid nitrogen
and stored at 280uC until further analysis.
Protein Isolation and Mass Spectrometry. Muscle protein
content was determined as previously described [19,22]. Approx-
imately 30 mg of muscle tissue was homogenized in ice-cold lysis
buffer as described [19,22]. Tissue was homogenized while still
frozen in an ice-cold buffer (10 ml/mg tissue) consisting of (final
concentrations): 20 mM HEPES, pH 7.6; 1 mM EDTA; 250 mM
sucrose, 2 mM Na3VO4; 10 mM NaF; 1 mM sodium pyrophos-
phate; 1 mM ammonium molybdate; 250 mM PMSF; 10 mg/ml
leupeptin; and 10 mg/ml aprotinin. After homogenized by a
polytron homogenizer on maximum speed for 30 sec, the
homogenate was cooled on ice for 20 min and then centrifuged
at 10,0006g for 20 min at 4uC; the resulting supernatant
containing 60 mg of lysate supernatant proteins was used for in-
gel digestion. Protein concentrations were determined by the
method of Lowry method. Muscle lysate proteins were separated
on 4–20% 1D linear gradient SDS polyacrylamide gels and each
lane was cut into 20 separate slices. Gel pieces were treated with
trypsin to digest proteins; the resulting mixture was desalted and
subjected to mass spectrometry.
HPLC-ESI-MS/MS was performed on a hybrid linear ion trap
(LTQ)-Fourier Transform Ion Cyclotron Resonance (FTICR)
mass spectrometer (LTQ FT; Thermo Fisher, San Jose, CA) fitted
with a PicoViewTM nanospray source (New Objective, Woburn,
MA). On-line capillary HPLC was performed using a Michrom
BioResources Paradigm MS4 micro HPLC (Auburn, CA) with a
PicoFritTM column (New Objective; 75 mm i.d., packed with
ProteoPepTM II C18 material, 300 A ˚). Samples were desalted
using an on-line Nanotrap (Michrom BioResources, Auburn, CA)
before being loaded onto the PicoFritTM column. HPLC
separations were accomplished with a linear gradient of 2 to
27% ACN in 0.1% FA in 70 min, a hold of 5 min at 27% ACN,
followed by a step to 50% ACN, hold 5 min and then a step to
80%, hold 5 min; flow rate, 300 nl/min. A ‘‘top-10’’ data-
dependent tandem mass spectrometry approach was utilized to
identify peptides in which a full scan spectrum (survey scan) was
acquired followed by collision-induced dissociation (CID) mass
spectra of the 10 most abundant ions in the survey scan. The
survey scan was acquired using the FTICR mass analyzer in order
to obtain high resolution and high mass accuracy data.
Data Analysis and Bioinformatics. Tandem mass spectra
were extracted from Xcalibur ‘‘RAW’’ files and charge states were
assigned using the Extract_MSN script (Thermo Fisher, San Jose,
CA). The fragment mass spectra were then searched against the
IPI_HUMAN_v3.59 database (80,128 entries, http://www.ebi.ac.
uk/IPI/) using Mascot (Matrix Science, London, UK; version 2.2).
The false discovery rate was determined by selecting the option to
GDM and the Skeletal Muscle Proteome
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used were: 10 ppm mass tolerance for precursor ion masses and
0.5 Da for production masses; digestion with trypsin; a maximum
of two missed tryptic cleavages; fixed modification of carboami-
domethylation; variable modifications of oxidation of methionine
and phosphorylation of serine, threonine and tyrosine. Probability
assessment of peptide assignments and protein identifications were
made through use of Scaffold (version Scaffold_2_00_06,
Proteome Software Inc., Portland, OR). Only peptides with $
95% probability were considered. Proteins that contained identical
peptides and could not be differentiated based on MS/MS analysis
alone were grouped.
Protein and gene ontology annotation were performed as
described, as were extraction of tandem mass spectra and
Figure 1. Work flow of statistical analysis of single proteins.
doi:10.1371/journal.pone.0106872.g001
GDM and the Skeletal Muscle Proteome
PLOS ONE | www.plosone.org 3 September 2014 | Volume 9 | Issue 9 | e106872verification of charge states and monoisotopic peak assignments
[19]. To quantify protein abundance, normalized spectral
abundance factors (NSAF)s were used [19]. Briefly, MS/MS
spectra assigned to a protein were normalized to the number of
amino acids for that protein, resulting in a spectral abundance
factor (SAF). Each SAF was normalized against the sum of all
SAFs in one sample, resulting in the NSAF value. This calculation
is represented by the following equation, where N is equal to the
number of proteins detected in a sample:
NSAFi~SAFi
,
X N
i~1
SAFi
Thus, NSAF values allow for direct comparison of a protein’s
abundance between individual runs in a fashion similar to
microarray data analysis. The reproducibility and linearity of this
method are described previously [19,23].
Study 2: Metabolic Analysis
Ethics Statement. Approval for this study was obtained from
the Mercy Hospital for Women’s Research and Ethics Committee
and written informed consent was obtained from all participants
prior to cesarean delivery.
Patients and Sample Collection. To extend our observa-
tions from Study 1, a larger cohort of ONGT and OGDM subjects
were studied. Pregnant women over 21 years of age were screened
for GDM at 24–28 weeks gestation and were diagnosed according
to the criteria set by the Australasian Diabetes in Pregnancy
Society (ADIPS), by either a fasting venous plasma glucose level of
5.5 (compared to 5.3 using CC criteria) and/or greater than
8.0 mmol/L (8.6 using CC criteria) glucose 2 h after a 75 g oral
glucose tolerance test. Applying these criteria results in a
prevalence of GDM of ,18% [23,24]. Only GDM patients
treated with insulin to control blood glucose levels were included.
Women with polycystic ovarian syndrome, pre-eclampsia, and
macrovascular complications were excluded. BMI was similarly
calculated from patients’ first antenatal visit (,12 weeks gestation)
and only women in both groups with a BMI of .30 kg/m
2 were
included.
Between 300 and 500 mg of pyramidalis skeletal muscle was
obtained from a total of 18 pregnant women undergoing elective
caesarean delivery (term, ,37 weeks gestation; 10 ONGT and 8
OGDM). The pyramidalis muscle is located anterior to the rectus
abdominus and is also of mixed fiber type [24,25]. Dissections of
skeletal muscle were obtained within 10 min of delivery and snap
frozen in liquid nitrogen and stored at 280uC until further
analysis. Tissues were also imbedded for histology to verify that
they were free from adipose or connective tissue contamination by
hemotoxylin and eosin staining as previously described [25,26].
For all deliveries in Study 2, spinal anesthesia and/or epidural
were used. All muscle samples were taken at the time of cesarean
delivery (between 0830 and 1500). Women delivering in the
morning hours were fasted overnight, women delivering after 1200
were fasted from 0730.
Plasma Measures. Maternal blood was collected by veni-
puncture at the time of diagnosis (fasting sample, oral glucose
tolerance test). Blood samples were immediately centrifuged at
1,500 g for 10 min and the plasma aliquoted into microfuge tubes
and samples were immediately stored at 280uC until assayed for
glucose and insulin. Blood glucose determination was performed
by the hospital pathology department using an automated glucose
oxidase/oxygen-rate method. Standard ELISA assay kit for insulin
(Diagnostic Systems Laboratories, Webster, TX; limit of detection
0.26 IU/mL) was purchased and used according to the
manufacturer’s instructions. Insulin resistance at time of diagnosis
was calculated using the homeostasis model assessment for insulin
resistance (HOMA-IR) method where HOMA-IR=fasting plas-
ma glucose (mmol/l) times fasting plasma insulin (mU/mL) divided
by 22.5 [26,27].
Mitochondrial Enzyme Activity Assays. Mitochondrial-
enriched supernatants (post 600 g) were prepared from frozen
skeletal muscle samples, as described [27]. Supernatants were used
to assay activity of respiratory chain enzyme complexes I, II, III,
and IV (C-I through C-IV, respectively); and citrate synthase (CS),
spectrophotometrically on a Synergy H1 microplate reader
(Biotek, Winooski, VT). Enzyme assays for respiratory chain
complexes and CS were performed as described [27,28] with
minor modifications for microplate reading. For C-I and C-II,
enzyme activities were calculated as initial rates (nmol/min). For
complexes III and IV, enzyme activities were calculated as the
first-order rate constants derived within 2–3 min of reaction
initiation. All assays were performed in duplicate. The protein
content of each sample was determined using a BCA assay. All
activities were normalized to the total protein content and to CS
activity (calculated as initial rate of reaction as nmol/min) of each
sample and expressed relative to the mean for NGT women.
Western Blot. Protein levels of MitoProfile total OXPHOS
antibody cocktail, AMPK, phosphoAMPK, PGC-1a and PPARa
were determined in the muscle biopsy samples with calnexin as
loading control as previously described [28]. OXPHOS antibody
cocktail measured specific subunits of C-I, C-II, C-III, and C-IV
(NDUFB8, SDHB, UQCRC2, and MT-CO1, respectively). All
antibody dilutions were 1:1,000 for primary antibodies and
1:10,000 for secondary antibodies, unless otherwise stated. All
results were expressed relative to the mean for NGT women.
Table 1. Clinical characteristics of the subjects for Study 1.
ONGT (n=6) OGDM (n=6)
Delivery BMI (kg/m
2) 34.262.3 37.562.1
Fasting Glucose (mmol/L) 4.260.2 5.360.3*
Insulin (mU/L) 11.363.2 19.564.8*
HOMA-IR 2.160.7 4.661.0*
Triglycerides (mg/dL) 161.0622.6 265.5640.3
Gravida 2.060.0 2.562.1
Parity 1.060.0 1.061.4
Data are mean 6 SEM. OGTT, oral glucose tolerance test. Independent t-test *P,0.05.
doi:10.1371/journal.pone.0106872.t001
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PGC-1a (host: rabbit), and PPARa (host: rabbit) antibodies were
purchased from Abcam (Cambridge, MA). AMPK (host: rabbit)
and phospho-AMPK (Thr172) (host: rabbit) antibodies were from
Cell Signaling Technology (Danvers, MA). Secondary antibodies
were purchased from Bio-Rad (Hercules, CA).
Mitochondrial DNA Copy Number. Approximately 15 mg
of skeletal muscle was homogenized and DNA was isolated by
phenol/chloroform extraction with ethanol precipitation. Mito-
chondrial DNA (mtDNA) copy number was then measured as
previously described [28].
Statistical Analyses
Statistical analyses were performed using IBM SPSS Statistics,
Version 22 (IBM Corp., Armonk, NY). For the Study 1 proteomic
analysis, a large number of proteins were assigned in at least one of
12 subjects studied (979 proteins; Table S1). A series of filters were
used to narrow the number of proteins that were used in
comparisons between groups (Figure 1). First only those proteins
with representation in at least three subjects from each group were
chosen (415 proteins). Of these, only those proteins with greater
than 1.5-fold difference between groups (22 proteins) were
examined for statistically significant differences between groups.
First, data were tested for normality using the Shapiro-Wilk test,
which were performed for ONGT and OGDM separately.
Table 2. Proteins with 1.5-fold difference between ONGT and OGDM, Study 1.
Gene Name Protein Function
Fold
Difference
t-test
P value
MYOM1 Myomesin 1 Structural protein 5.21 0.07
HSPA1A/1B Heat shock 70 kDa
protein 1A/1B
Stress response 2.98 0.09
ME1 NADP-dependent
malic enzyme
Pyruvate metabolism 2.39 0.09
CMBL Carboxymethylenebutenolidase
homolog
Cysteine Hydrolase 2.30 0.01*
PPP3CB Calmodulin-dependent
calcineurin A b
Calcium homeostasis 2.22 0.02*
CAMK2A Calcium/calmodulin-dependent
protein kinase 2 a
Calcium homeostasis 2.17 0.15
FKBP3 Peptidyl-prolyl cis-trans
isomerase FKBP3
Protein folding 1.86 0.38
ERP29 Endoplasmic reticulum
resident protein 29
Protein folding 1.75 0.40
CD36 Platelet glycoprotein 4 Fatty acid transport 1.73 0.05*
LRRC47 Leucine-rich repeat-
containing protein 47
N/A 1.71 0.30
TUBA8 Tubulin alpha-8 chain Cytoskeleton
organization
21.54 0.10
CAPZA2 F-actin-capping
protein subunit alpha-2
Cytoskeleton
organization
21.58 0.12
NDUFV2 NADH dehydrogenase
flavoprotein 2
Oxidative
phosphorylation
21.59 0.04*
NDUFS3 NADH dehydrogenase
iron-sulfur protein 3
Oxidative
phosphorylation
21.60 0.03*
ANXA4 Annexin A4 Calcium
binding protein
21.65 0.05*
NDUFS8 NADH dehydrogenase
iron-sulfur protein 8
Oxidative
phosphorylation
21.74 0.07
PSMA2 Proteasome subunit
alpha type-1
Proteolysis 21.97 0.04*
TTR Transthyretin Thyroid hormone
transport (circulation)
21.97 0.10
SERPINC1 Antithrombin-III Serine protease
inhibitor (circulating)
22.03 0.12
AHSG Alpha-2-HS-glycoprotein Calcium transport
(circulating)
22.07 0.07
CP Ceruloplasmin Iron transport
(circulating)
22.07 0.19
SNTA1 Alpha1-syntrophin Ion transport
(including calcium)
22.93 0.03*
doi:10.1371/journal.pone.0106872.t002
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Mann Whitney U tests where data were not normally distributed,
and remaining proteins were subjected to independent t-tests.
Study 2 was powered off our previous analysis of skeletal muscle
enzyme activity in pregnant women [28–30], which showed a
calculated effect size of 1.32 (averaged for C-I, C-II, and C-III) for
differences between NGT and GDM women. We calculated 80%
power with n=10 subjects per group where a=0.05 for two-sided
independent t-tests. Data were tested for normality using the
Shapiro-Wilk test, which were performed for ONGT and OGDM
separately. Independent t-tests were performed on raw or log-
transformed data where data were not normally distributed.
Statistical difference is indicated by P#0.05. Data are expressed as
the mean 6 SEM.
Results
Study 1: Proteomic Analysis
Patient Characteristics. Patient characteristics for the
women in Study 1 are shown in Table 1. Women in the ONGT
(n=6) and OGDM (n=6) groups were of similar BMI. As
expected, OGDM women had higher fasting blood glucose and
insulin values, which translated to higher HOMA-IR scores (P,
0.05).
Mitochondrial and Calcium Signaling Proteins are
Altered in Women with GDM. Of the 979 unique proteins
identified by tandem MS/MS mass spectrometry and NSAF
analysis (Table S1), 22 met our criteria for statistical comparison
between the OGDM and ONGT participants (protein detectable
in at least three subjects per group and greater than 1.5-fold
difference between groups; Table 2). Of these, eight proteins were
statistically different between the groups (P#0.05). Two of these
proteins were subunits of ETS Complex I (C-I; NDUFV2 and
NDUFS3), which were reduced by 60% in women with OGDM
(P,0.05), while a third subunit of C-I (NDUFS8) tended to be
reduced by 75% in the women with OGDM, compared with
ONGT women (P=0.07). Fatty acid transporter CD36 was
increased by almost 75% in women with OGDM (P=0.05). In
addition, proteasome subunit alpha-1, a protein involved in
protein degradation, was reduced by nearly 2-fold in women with
OGDM (P,0.05). Surprisingly, several proteins involved in
calcium homeostasis and calcium-dependent cellular signaling
were also altered in skeletal muscle of women with OGDM,
including calmodulin-dependent calcineurin A b (PPP3CB), which
was increased by over 2-fold in women with OGDM compared
with ONGT women (P,0.05). Similarly, calcium/calmodulin-
dependent protein kinase type II, subunit A (CaMKIIa), tended to
be higher in women with OGDM, though this was not
significantly different between groups (+2-fold in GDM,
P=0.15). Furthermore, annexin A4, a calcium binding protein,
was decreased by 65% in the women with OGDM (P=0.05) and
a1-syntrophin, a cellular localization protein involved in ion
transport and cellular signaling, including calcium ion flux, was
decreased by nearly 3-fold in women with OGDM (P,0.05).
Study 2: Metabolic Analysis
Patient Characteristics. For Study 2, we followed up the
results from Study 1 in a larger, separate cohort of OGDM and
ONGT women (Table 3). The ONGT (n=10) tended to be more
obese than the OGDM women (n=8; P=0.06), though fasting
blood glucose and 1 and 2 hour OGTT glucose values were higher
in OGDM than ONGT women (P,0.05).
Mitochondrial Enzyme Activity is Reduced in Women
with GDM. Because we observed reduced protein content of
mitochondrial oxidative phosphorylation subunits (Study 1,
Table 2), we measured two common markers of mitochondrial
content (mitochondrial DNA copy number [mtDNA] and CS
activity) in Study 2. However, mtDNA tended to be 30% lower in
OGDM compared to ONGT women (P=0.10; Figure 2A), while
CS activity tended to be 30% higher in the women with OGDM
(P=0.06; Figure 2B).
Next, given the reduced content of several C-I subunits
(NDUFV2, NDUFS3) in skeletal muscle of OGDM compared to
ONGT women (Study 1), we determined whether the activity of
key enzymes involved in mitochondrial oxidative phosphorylation
was also different between groups in Study 2. We found that
women OGDM women exhibit reduced activity of C-I and C-III,
(by 45% and 45%, and 30%, respectively; Figure 2C&E ;P ,
0.05) and a trend for reduced C-IV activity (by 30%; Figure 2F;
P=0.06) compared to ONGT women. However, OXPHOS
protein content was not similarly reduced (Figure 3A, C,&D).
There were no differences in C-II activity or protein content
(Figure 2D &3 B).
To examine whether transcriptional regulators of mitochondrial
biogenesis were affected, we measured PPARa and PGC-1a
protein content, though these were not different between ONGT
and OGDM women (Figure 4A&B ; ns). Lastly, because AMPK
is a calcium-dependent protein involved in cellular metabolism
Table 3. Clinical characteristics of the subjects for Study 2.
ONGT (n=10) OGDM (n=8)
Maternal age (years) 33.461.8 34.161.1
12-week BMI (kg/m
2)3 8 . 4 61.7 33.861.5
Delivery BMI (kg/m
2)4 1 . 2 62.2 36.861.6
Glucose: 0 h OGTT (mmol/L) 4.760.1 5.560.2*
Glucose: 1 h OGTT (mmol/L) 7.460.6 9.960.6*
Glucose: 2 h OGTT (mmol/L) 5.360.3 7.760.7*
Gestational age (weeks) 38.760.2 38,260.4
Gravida 3.560.6 3.060.3
Parity 2.460.4 2.060.3
Neonate birth weight (g) 3554.56107.1 3616.16183.0
Data are mean 6 SEM. OGTT, oral glucose tolerance test. Independent t-test *P,0.05.
doi:10.1371/journal.pone.0106872.t003
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phosphorylation and found that Thr172 phosphorylation of
AMPK was markedly downregulated by 75% in OGDM
compared to ONGT women (Figure 4C&D ).
Discussion
The present study is the first proteomic analysis of skeletal
muscle tissue from obese, pregnant women with GDM compared
with their obese, NGT counterparts. In this hypothesis-generating
analysis we found that several proteins of the mitochondrial ETS
were downregulated in the women with GDM, a factor that was
corroborated by reduced activity of several enzyme complexes of
Figure 2. Mitochondrial enzyme activity is reduced in skeletal muscle of OGDM women. Quantitative bar graphs of mitochondrial DNA
copy number (A) and enzyme activity of citrate synthase (B) complex I (C), complex II (D), complex III (E), and complex IV (F) of the respiratory chain in
pyramidalis muscle collected during scheduled cesarean section. Data are mean 6 SEM. *P,0.05 vs. NGT.
doi:10.1371/journal.pone.0106872.g002
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women. Proteomic analysis also revealed disrupted calcium
signaling/homeostasis proteins in skeletal muscle of OGDM
women. Subsequent measures also showed a pronounced reduc-
tion in the phosphorylation of AMPK in skeletal muscle in
OGDM compared to ONGT women, which has been linked to
both calcium homeostasis and reduced oxidative metabolism.
Obese, insulin resistant humans often exhibit reduced skeletal
muscle mitochondrial function when compared with normal
weight, insulin sensitive individuals, generally in the form of
reduced electron transport flux or ATP turnover [31–34]. We
Figure 3. Mitochondrial respiratory chain complex proteins are not different between ONGT and OGDM women. Complex I (A),
complex II (B), complex III (C), complex IV (D). Representative Western blots where calnexin is used as loading control (E).
doi:10.1371/journal.pone.0106872.g003
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PLOS ONE | www.plosone.org 8 September 2014 | Volume 9 | Issue 9 | e106872Figure 4. AMPK phosphorylation is reduced in OGDM women, though regulators of mitochondrial biogenesis are not. Quantitative
bar graphs of PPARa (A) and PGC-1a (B), total AMPK (C), and phospho-AMPK (D) protein content in pyramidalis muscle collected during scheduled
cesarean section. Representative Western blots where calnexin is used as loading control (E). Data are mean 6 SEM. *P,0.05 vs. NGT.
doi:10.1371/journal.pone.0106872.g004
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cantly lower skeletal muscle mitochondrial C-I subunit protein
content (Study 1) and enzyme activity (Study 2) compared to
obese, NGT women. Even though there was a trend for reduced
mtDNA copy number in the OGDM women, the trend for
increased CS activity in these same women, makes it difficult to
determine whether mitochondrial content was reduced in the
women with GDM. However, given that enzyme activity data
were normalized to CS activity in Study 2, the lower enzyme
activities in the OGDM women do not appear to be the result of
lower mitochondrial content and these discrepancies in mitochon-
drial content simply highlight the fact that these data are markers
of mitochondrial content, not direct measures. For this reason we
also measured upstream regulators of oxidative metabolism and
mitochondrial biogenesis (PGC-1a and PPARa) and found that
they were not different between the OGDM and ONGT women.
These data indicate that mitochondrial functional capacity may be
linked to specific subunit protein content rather than global
mitochondrial deficits in the skeletal muscle of women with
OGDM. Thus, in this cohort where the principal differences
between the OGDM and ONGT women is impaired glucose
tolerance, these results suggest that reduced mitochondrial enzyme
capacity may be an important determinant of excessive glucose
intolerance during pregnancy, perhaps contributing to postpartum
diabetes risk. However, the association between reduced skeletal
muscle mitochondrial capacity and T2DM is not universally
reported. For example, Asian Indians with T2DM show greater
skeletal muscle mitochondrial activity than their non-diabetic
counterparts [34,35], and Boushel et al. [35–37] report similar
mitochondrial respiration rates in permeabilized muscle fibers
from obese, type 2 diabetics compared with non-diabetic,
overweight counterparts, suggesting that the relationship between
T2DM and reduced mitochondrial capacity is not causal.
Gestational diabetes, like T2DM, is characterized by both insulin
resistance and pancreatic beta cell dysfunction [8,36,37]. There-
fore, in addition to factors such as skeletal muscle mitochondrial
dysfunction and skeletal muscle insulin signaling [8,38–40], which
can exacerbate insulin resistance, factors determining beta cell
function likely play a prominent role in the development of GDM
and subsequent T2DM postpartum.
Calcium homeostasis and calcium-dependent signaling play
important roles in many skeletal muscle processes in addition to
muscle contraction, such as insulin-mediated glucose uptake,
AMPK signaling and mitochondrial biogenesis [38–41]. Our
proteomic analysis revealed decreased a1-syntrophin and annexin
A4, proteins involved in intracellular calcium signaling/homeo-
stasis. In addition, we observed large increases in both calcineurin
A and CaMKIIa in OGDM compared with ONGT women,
though differences in CaMKIIa did not reach statistical signifi-
cance. Such data suggest a disruption in calcium handling in
skeletal muscle of women with GDM that warrants further
investigation into its role in insulin signaling and mitochondrial
capacity.
Alpha 1-syntrophin is a member of the syntrophin family of
scaffold proteins that interacts with many signaling proteins,
linking them with various cell surface receptors, ion channels, and
downstream effectors [41–43]. In particular, a1-syntrophin,
interacts with dystrophin and related proteins [38,41–44] and
disruption of the dystrophin-syntrophin complex has been
suggested to promote the excessive calcium influx and altered
MAPK and GTPase signaling observed in muscular dystrophy
[38,41,44–46]. In this context, silencing of a1-syntrophin in
myotube cultures induces cellular calcium influx via store-operated
calcium channels [39,40,45,46]. Thus, the observed reduction in
a1-syntrophin in the skeletal muscle of OGDM women in our
study may affect myocellular calcium levels. Contrary to transient
increases in intramyocellular calcium that induce AMPK phos-
phorylation, such as occurs with muscle contraction, sustained
elevations of intramyocellular calcium can reduce AICAR-induced
AMPK phosphorylation in myotube cultures, which appears to be
regulated by elevated CaMKII [29,39,40]. Thus, sustained
elevations in cellular calcium may induce CaMKII to inhibit
AMPK phosphorylation. As a potent activator of lipid oxidation
and mitochondrial biogenesis [10,11,29], the reduced AMPK
phosphorylation observed in Study 2 could explain their reduced
mitochondrial enzyme capacity via calcium regulatory mecha-
nisms. Though we did not observe differences in overall
mitochondrial content in Study 2, as estimated by mtDNA copy
number and citrate synthase activity, it is possible that there was a
deficit in content of specific subunit proteins, which contributed to
reduced enzyme activity. For example, the C-I molecule contains
45 subunit proteins [47]. Our proteomic analysis only identified 24
C-I subunit proteins assigned in at least 1 individual (Table S1), of
which only two were statistically different between groups. This
suggests that, while overall subunit content of C-I is not different in
skeletal muscle of the OGDM women, content of specific,
important C-I subunit proteins is reduced, resulting in reduced
mitochondrial enzyme activity. Indeed, gene silencing of NDUFS3
and mutations in the NDUFV2 gene have been shown to lead to
mitochondrial dysfunction, hypertrophic cardiomyopathy, and
Leigh’s Syndrome [48,49]. Thus, calcium regulatory control of
AMPK phosphorylation and mitochondrial enzyme capacity may
have clinical implications that may partially explain why physical
activity interventions in women with GDM, for the control
glycemia and prevention of its progression to T2DM, are
disappointing and often associated with a high non-compliance
rate [10,11,50]. While this is the first report of reduced a1-
syntrophin in human insulin resistant skeletal muscle, similar
observations have been made in diabetic Goto-Kakizaki rats,
where skeletal muscle dystrophin and a1-syntrophin content was
markedly reduced and thought to be a contributor to the excessive
insulin resistance observed in these animals [50,51].
Annexin A4 is a lipid-binding protein involved in exocytosis and
ion transport in a calcium-dependent manner [51,52]. Among its
many functions, annexin A4 interacts with the p50 subunit of NF-
kB, reducing is transcriptional activity [8,52,53]. Thus, the
inflammatory cascade may be enhanced in skeletal muscle where
annexin A4 protein is reduced. This may be one mechanism
whereby inflammation is elevated in skeletal muscle of women
with GDM, as we have shown previously [8,53]. As a result, serine
phosphorylation of JNK and/or p70S6 kinase may link inflam-
mation with disrupted insulin signaling in skeletal muscle of
women with GDM [8,53,54]. While this is the first report of
reduced annexin A4 in skeletal muscle of GDM patients, members
of our group have recently reported reduced content of other
annexin proteins (A2, A5, A6) in placental tissue from obese GDM
patients [54,55], suggesting a universal disruption of annexin
protein content in pregnant women with GDM.
Calcineurin A was reduced in skeletal muscle of OGDM
women. Calcineurin A is the catalytic subunit of calcineurin that
forms a heterodimer with the calcineurin B regulatory subunit
[55,56]. Once activated by calcium/calmodulin, calcineurin
stimulates insulin sensitizing pathways and has also been shown
to induce lipid oxidation and mitochondrial biogenesis pathways,
including increased expression of CD36 and all of the ETS
complexes [56,57], which may explain increased CD36 protein in
OGDM women in the proteomic analysis. Increased calcineurin A
may also account for the slight, yet non-significant increases in
GDM and the Skeletal Muscle Proteome
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women (Study 2). However, studies show that calcineurin
expression is induced in response to mitochondrial stress and
mtDNA damage [57,58]. For example, in early stage diabetic
cardiomyopathy, mitochondrial stress is commonly observed,
along with disrupted calcium homeostasis, elevated calcineurin,
and insulin resistance [28,58]. While these observations may seem
paradoxical given calcineurin action, they seem to suggest a
compensatory function of calcineurin, with regard to mitochon-
drial biogenesis and insulin sensitivity, which may be precluded in
cardiac muscle of diabetic cardiomyopathy patients. Perhaps a
similar compensatory increase in calcium is observed in skeletal
muscle of GDM patients in response to mitochondrial stress.
We have previously reported that obese women with mild, diet-
treated GDM have similar skeletal muscle mitochondrial enzyme
activity to obese NGT pregnant women [28,59,60]. Here, we have
found that those with more severe GDM (insulin-treated) exhibit
lower mitochondrial enzyme activity for C-I and C-III than obese
NGT pregnant women, despite the tendency for lower BMI,
suggesting that the extent of glucose intolerance may play a more
important role in skeletal muscle mitochondrial enzyme capacity
than BMI in these women. This is further corroborated by the fact
that the women with insulin treated GDM presented here had
similar BMIs as the women with diet-treated GDM reported
previously [28]. While it is possible that exogenous insulin
administration may have induced the observed proteomic or
enzymatic differences in the OGDM women, it is equally plausible
that, due to skeletal muscle insulin resistance of the OGDM
women, exogenous insulin simply equalized the effect of insulin on
skeletal muscle tissues to those observed in the non-insulin treated
women. Nevertheless, reduced mitochondrial enzyme activity in
the OGDM women does not appear to be the result of differences
in total mitochondrial content, but rather may be the result of
reduced subunit protein content. Even though we discovered
reduced content of two C-I subunits, and a trend for reduced
content of a third C-I subunit in our proteomic analysis, we did
not observe differences in total OXPHOS content, which is likely
due to the fact that the OXPHOS antibody cocktail only measures
the NDUFB8 C-I subunit. Nevertheless, we must recognize that
these observations can only be extended to obese women
diagnosed with GDM, and may differ for those women with less
severe GDM (diet-treated).
GDM women and their offspring are a population which
globally and significantly contributes to the escalation of T2DM
and childhood obesity and our proteomic analysis of skeletal
muscle from obese pregnant women revealed that proteins
involved in mitochondrial oxidative phosphorylation are reduced
in OGDM compared to their ONGT counterparts. These
observations were corroborated by reduced skeletal muscle
mitochondrial enzyme activity in a larger cohort of obese pregnant
women. We further demonstrated that several proteins involved in
calcium homeostasis/signaling were altered in obese women with
GDM, several of which may be linked to disrupted insulin
signaling and reduced mitochondrial activity. Such disturbances in
calcium homeostasis proteins could contribute to the inflamma-
tion, insulin resistance, and altered substrate metabolism observed
in skeletal muscle of OGDM patients, consequently shunting
maternal nutrients to the growing fetus. Furthermore, disruption
of calcium homeostasis could help explain the high failure rate of
exercise intervention studies designed to treat women with GDM
during pregnancy and/or to prevent the development of T2DM
postpartum [59,60].
In conclusion, this exploratory analysis identifies several calcium
regulatory proteins that could represent novel risk factors for both
the development of GDM and the progression to T2DM. Larger,
more targeted studies are required to confirm these exploratory
analyses. Further examination of calcium regulatory proteins
could reveal an important link between insulin resistance and
reduced mitochondrial activity in obese women with GDM that
could potentially be targeted for strategies geared toward
prevention and treatment of T2DM in this rapidly growing
cohort of at risk women.
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